ArticleCirculation1999
Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.
Article in Circulation, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000463. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Post Coronary Artery Bypass Graft (CABG) Study
Who cites it
15 citing papers in PubMed, 119 citations in OpenAlex.
- Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.Clinical cardiology · 2001Trial
- Determinants of graft patency after coronary artery bypass grafting.Frontiers in cardiovascular medicine · 2026Review
- Radiotherapy inhibits neointimal hyperplasia after artificial vascular replacement through Skp2/P27kip1.Journal of radiation research · 2022Article
- Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA.Gene therapy · 2013Article
- Conduits for coronary bypass: vein grafts.The Korean journal of thoracic and cardiovascular surgery · 2012Article
- Oversized vein grafts develop advanced atherosclerosis in hypercholesterolemic minipigs.BMC cardiovascular disorders · 2012Article
- Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts.Journal of cardiothoracic surgery · 2011Article
- Article
- Prior coronary artery bypass graft surgery patients undergoing diagnostic coronary angiography have multiple uncontrolled coronary artery disease risk factors and high risk for cardiovascular events.Heart and vessels · 2009Article
- Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data.Current atherosclerosis reports · 2006Review
- [The importance of cholesterol-lowering in patients after coronary artery bypass surgery].Clinical research in cardiology : official journal of the German Cardiac Society · 2006Article
- Insights into the pathogenesis of vein graft disease: lessons from intravascular ultrasound.Cardiovascular ultrasound · 2004Review
- Treatment of dyslipidemia in pre- and postmenopausal women with and without known atherosclerotic cardiovascular disease.Current cardiology reports · 2001Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundThe NHLBI Post Coronary Artery Bypass Graft trial (Post CABG) showed that aggressive compared with moderate lowering of low-density lipoprotein-cholesterol (LDL-C) decreased obstructive changes in saphenous vein grafts (SVGs) by 31%.1 Using lovastatin and cholestyramine when necessary, the annually determined mean LDL-C level ranged from 93 to 97 mg/dL in aggressively treated patients and from 132 to 136 mg/dL in the others (P<0.001). METHODS AND
resultsThe present study evaluated the treatment effect in subgroups defined by age, gender, and selected coronary heart disease (CHD) risk factors, ie, smoking, hypertension, diabetes mellitus, high-density lipoprotein cholesterol (HDL-C) <35 mg/dL, and triglyceride serum levels >/=200 mg/dL at baseline. As evidenced by similar odds ratio estimates of progression (lumen diameter decrease >/=0.6 mm) and lack of interactions with treatment, a similar beneficial effect of aggressive lowering was observed in elderly and young patients, in women and men, in patients with and without smoking, hypertension, or diabetes mellitus, and those with and without borderline high-risk triglyceride serum levels. The change in minimum lumen diameter was in the same direction for all subgroup categories, without significant interactions with treatment.
conclusionsAggressive LDL-C lowering delays progression of atherosclerosis in SVGs irrespective of gender, age, and certain risk factors for CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.